Dova Pharmaceuticals, Inc. (DOVA)
(Delayed Data from NSDQ)
$9.62 USD
+0.18 (1.91%)
Updated May 3, 2019 04:00 PM ET
After-Market: $9.64 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.62 USD
+0.18 (1.91%)
Updated May 3, 2019 04:00 PM ET
After-Market: $9.64 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Will Dova Pharmaceuticals (DOVA) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Dova Pharmaceuticals (DOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dova Pharmaceuticals Enters Overbought Territory: Is A Drop Coming?
by Zacks Equity Research
Dova Pharmaceuticals has moved higher as of late, but there could definitely be trouble on the horizon for this company.
Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8%
by Zacks Equity Research
Dova Pharmaceuticals (DOVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Dova Pharmaceuticals (DOVA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dova Pharmaceuticals (DOVA) delivered earnings and revenue surprises of -5.26% and -37.55%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Dova Pharmaceuticals (DOVA) in Focus: Stock Moves 9.1% Higher
by Zacks Equity Research
Dova Pharmaceuticals (DOVA) shares rose more than 9% in the last trading session, amid huge volumes.
Bausch Gains 38.9% YTD on Product Launches & Debt Reduction
by Zacks Equity Research
Bausch (BHC) is currently focusing on widening its ophthalmology and dermatology portfolio.
Dova Receives Approval for Doptelet in Europe, Stock Up
by Zacks Equity Research
Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.
Implied Volatility Surging for Dova Pharmaceuticals (DOVA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Dova Pharmaceuticals (DOVA) stock based on the movements in the options market lately.
Dova Pharmaceuticals (DOVA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dova Pharmaceuticals (DOVA) delivered earnings and revenue surprises of 14.71% and 15.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Dova (DOVA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Dova (DOVA) stock based on the movements in the options market lately.
Factors to Know Ahead of Herbalife's (HLF) Q4 Earnings
by Zacks Equity Research
Herbalife (HLF) is likely to gain from its direct-selling network, product portfolio and solid volumes. However, unfavorable currency movements and stiff competition may hurt the bottom line.
Dova Pharmaceuticals (DOVA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dova Pharmaceuticals (DOVA) delivered earnings and revenue surprises of 15.85% and 10.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?